JP7828274B2 - 眼疾患を治療するための方法 - Google Patents

眼疾患を治療するための方法

Info

Publication number
JP7828274B2
JP7828274B2 JP2022515650A JP2022515650A JP7828274B2 JP 7828274 B2 JP7828274 B2 JP 7828274B2 JP 2022515650 A JP2022515650 A JP 2022515650A JP 2022515650 A JP2022515650 A JP 2022515650A JP 7828274 B2 JP7828274 B2 JP 7828274B2
Authority
JP
Japan
Prior art keywords
weeks
vegf antagonist
disease activity
dose
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022515650A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547537A (ja
JP2022547537A5 (cg-RX-API-DMAC7.html
Inventor
マリア クロタール マーガロン,フィリップ
ゲキーヴァ,マルガリータ
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2022547537A publication Critical patent/JP2022547537A/ja
Publication of JP2022547537A5 publication Critical patent/JP2022547537A5/ja
Priority to JP2025260627A priority Critical patent/JP2026072102A/ja
Application granted granted Critical
Publication of JP7828274B2 publication Critical patent/JP7828274B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022515650A 2019-09-13 2020-09-11 眼疾患を治療するための方法 Active JP7828274B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025260627A JP2026072102A (ja) 2019-09-13 2025-12-17 眼疾患を治療するための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962899892P 2019-09-13 2019-09-13
US62/899,892 2019-09-13
US202062971405P 2020-02-07 2020-02-07
US62/971,405 2020-02-07
PCT/IB2020/058459 WO2021048806A1 (en) 2019-09-13 2020-09-11 Methods for treating ocular diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025260627A Division JP2026072102A (ja) 2019-09-13 2025-12-17 眼疾患を治療するための方法

Publications (3)

Publication Number Publication Date
JP2022547537A JP2022547537A (ja) 2022-11-14
JP2022547537A5 JP2022547537A5 (cg-RX-API-DMAC7.html) 2023-08-23
JP7828274B2 true JP7828274B2 (ja) 2026-03-11

Family

ID=72521675

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022515650A Active JP7828274B2 (ja) 2019-09-13 2020-09-11 眼疾患を治療するための方法
JP2025260627A Pending JP2026072102A (ja) 2019-09-13 2025-12-17 眼疾患を治療するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025260627A Pending JP2026072102A (ja) 2019-09-13 2025-12-17 眼疾患を治療するための方法

Country Status (11)

Country Link
US (1) US12649781B2 (cg-RX-API-DMAC7.html)
EP (1) EP4028128A1 (cg-RX-API-DMAC7.html)
JP (2) JP7828274B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220062279A (cg-RX-API-DMAC7.html)
CN (1) CN114375201A (cg-RX-API-DMAC7.html)
AU (1) AU2020347575A1 (cg-RX-API-DMAC7.html)
CA (1) CA3149706A1 (cg-RX-API-DMAC7.html)
IL (1) IL289436A (cg-RX-API-DMAC7.html)
MX (1) MX2022003101A (cg-RX-API-DMAC7.html)
TW (1) TW202116802A (cg-RX-API-DMAC7.html)
WO (1) WO2021048806A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
AU2020347575A1 (en) 2019-09-13 2022-03-17 Novartis Ag Methods for treating ocular diseases
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
TW202337496A (zh) * 2022-03-17 2023-10-01 瑞士商諾華公司 治療新生血管性年齡相關性黃斑點退化之方法
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1802334E (pt) 2004-10-21 2012-11-28 Genentech Inc Método para tratamento de doenças neovasculares intraoculares
KR20180005753A (ko) 2008-06-25 2018-01-16 에스바테크 - 어 노바티스 컴파니 엘엘씨 Vegf를 억제하는 안정하고 가용성인 항체
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
RU2653753C1 (ru) 2008-06-25 2018-05-14 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα
PE20120322A1 (es) 2009-07-07 2012-04-14 Boehringer Ingelheim Int Composicion farmaceutica que comprende faldaprevir o una sal del mismo en un vehiculo auto-emulsionante
US20160220675A1 (en) 2013-09-11 2016-08-04 Glenn Abrahmsohn Hypertonic antimicrobial therapeutic compositions
US11104730B2 (en) 2013-11-20 2021-08-31 Regeneren Pharmaceuticals, Inc. Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
ES2642723B1 (es) 2016-05-12 2018-10-22 Servizo Galego De Saúde (Sergas) Uso de los niveles de anticuerpos anti-CD26 como biomarcadores de enfermedades autoinmunes y/o inflamatorias.
MX2020009140A (es) 2018-03-16 2020-09-28 Novartis Ag Metodos para el tratamiento de enfermedades oculares.
CN113194993A (zh) 2018-12-18 2021-07-30 诺华股份有限公司 含高浓度抗vegf抗体的蛋白质溶液配制品
AU2020347575A1 (en) 2019-09-13 2022-03-17 Novartis Ag Methods for treating ocular diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Clinical Ophthalmology,2019年07月24日,13,pp.1323-1329
F1000Research,2019年08月12日,8(F1000 Faculty Rev),1413, pp.1-10
Journal of Diabetes and Its Complications,2019年08月15日,33,107417, pp.1-9
Ophthalmology,2019年04月12日,2020, 127,pp.72-84

Also Published As

Publication number Publication date
CN114375201A (zh) 2022-04-19
US12649781B2 (en) 2026-06-09
US20240052024A1 (en) 2024-02-15
IL289436A (en) 2022-02-01
EP4028128A1 (en) 2022-07-20
TW202116802A (zh) 2021-05-01
MX2022003101A (es) 2022-04-06
JP2022547537A (ja) 2022-11-14
CA3149706A1 (en) 2021-03-18
AU2020347575A1 (en) 2022-03-17
KR20220062279A (ko) 2022-05-16
JP2026072102A (ja) 2026-04-30
WO2021048806A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
AU2021286278C1 (en) Methods for treating ocular diseases
US20260098085A1 (en) Methods for treating age-related macular degeneration
JP2022547537A (ja) 眼疾患を治療するための方法
US20230416351A1 (en) Vegf antagonist for use in methods for treating ocular diseases
CN116710137A (zh) 用于在治疗眼部疾病的方法中使用的vegf拮抗剂
JP2025509568A (ja) 新生血管加齢性黄斑変性を治療する方法
RU2776850C2 (ru) Способы лечения глазных заболеваний
RU2771900C2 (ru) Способ лечения болезней глаз

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230810

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250813

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260227

R150 Certificate of patent or registration of utility model

Ref document number: 7828274

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150